Tracy Courtney
Neurology · Ellicott City, MDNPI 1437477593
Payments from drug & device makers
Across 160 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$360
- AstraZeneca$206
- Novartis$186
- Amneal Pharmaceuticals LLC$169
- UCB, Inc.$157
- Biohaven Pharmaceutical Holding Company Ltd.$122
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$482%
- Food & beverage$2,60798%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 25 | $360 |
| AstraZeneca | 7 | $206 |
| Novartis | 11 | $186 |
| Amneal Pharmaceuticals LLC | 11 | $169 |
| UCB, Inc. | 10 | $157 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $122 |
| Lilly USA, LLC | 7 | $109 |
| Teva Pharmaceuticals USA, Inc. | 6 | $104 |
| EMD Serono, Inc. | 4 | $104 |
| Acadia Pharmaceuticals Inc | 7 | $103 |
| Amgen | 7 | $96 |
| Upsher-smith Laboratories LLC | 3 | $74 |
| Genentech USA, Inc. | 5 | $73 |
| Biohaven Pharmaceuticals, Inc. | 5 | $72 |
| Avanir Pharmaceuticals, Inc. | 5 | $69 |
| Assertio Therapeutics, Inc. | 3 | $62 |
| Pfizer | 3 | $51 |
| SK Life Science, Inc. | 3 | $50 |
| Greenwich Biosciences, Inc. | 2 | $49 |
| Sanofi | 3 | $48 |
| AbbVie(2 entities) | 3 | $48 |
| Acorda Therapeutics, Inc | 3 | $48 |
| Neurelis, Inc. | 2 | $30 |
| GE HealthCare | 1 | $30 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Adamas Pharmaceuticals, Inc. | 2 | $25 |
| Bausch Health US, LLC | 1 | $25 |
| Akcea Therapeutics, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| MDD US Operations, LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$2,655 in reported general payments places this provider in the 50th percentile of 442 neurology providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 12 | $101,738 |
| QuliptaAtogepant | 23 | $24,722 |
| UbrelvyUbrogepant | 16 | $15,936 |
| Lacosamide | 26 | $2,275 |
| Memantine Hcl | 90 | $993 |
| Oxcarbazepine | 32 | $893 |
| Rivastigmine | 14 | $865 |
| Donepezil Hcl | 147 | $851 |
| Primidone | 93 | $801 |
| Fludrocortisone Acetate | 27 | $754 |
| Gabapentin | 94 | $659 |
| Propranolol Hcl ErPropranolol Hcl | 26 | $654 |
| Topiramate | 102 | $595 |
| Levetiracetam | 35 | $560 |
| Nortriptyline Hcl | 56 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $360 | $101,73812 claims |
| AbbVieQulipta, Ubrelvy | $48 | $40,65839 claims |
| Upsher-smith Laboratories LLCTopiramate | $74 | $595102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 442 neurology providers in Maryland.
Other neurology in Ellicott City
- Jose MasdeuBethesda$5.8M
- Ellen MowryBaltimore$5.7M
- Daniel BeckerLutherville$4.2M
- Michael PolydefkisBaltimore$4.1M
- Pavel KleinBethesda$3.2M
- Jeffrey RothsteinBaltimore$3M
- Pavan BhargavaBaltimore$2.8M
- Thomas CrawfordBaltimore$2.4M
- Nicholas MaragakisBaltimore$2.2M
- Shiv SaidhaBaltimore$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.